JP2014510782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510782A5 JP2014510782A5 JP2014504431A JP2014504431A JP2014510782A5 JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5 JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 102000034534 Cotransporters Human genes 0.000 claims 3
- 108020003264 Cotransporters Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- -1 cyano, carboxy Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475493P | 2011-04-14 | 2011-04-14 | |
| US61/475,493 | 2011-04-14 | ||
| PCT/IB2012/051798 WO2012140596A1 (en) | 2011-04-14 | 2012-04-12 | Glycoside derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510782A JP2014510782A (ja) | 2014-05-01 |
| JP2014510782A5 true JP2014510782A5 (https=) | 2015-06-11 |
Family
ID=46028034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504431A Pending JP2014510782A (ja) | 2011-04-14 | 2012-04-12 | グリコシド誘導体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8722633B2 (https=) |
| EP (1) | EP2697240B1 (https=) |
| JP (1) | JP2014510782A (https=) |
| KR (1) | KR20140019834A (https=) |
| CN (1) | CN103619862A (https=) |
| AU (1) | AU2012241426A1 (https=) |
| BR (1) | BR112013026361A2 (https=) |
| CA (1) | CA2832951A1 (https=) |
| EA (1) | EA201391524A1 (https=) |
| MX (1) | MX2013011926A (https=) |
| WO (1) | WO2012140596A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2719656T3 (es) | 2011-06-01 | 2019-07-11 | Green Cross Corp | Derivados de difenilmetano novedosos como inhibidores del SGLT2 |
| US9200025B2 (en) * | 2012-11-20 | 2015-12-01 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
| ES2605886T3 (es) | 2013-09-27 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Derivados de glucopiranosilo y sus usos en medicina |
| CN110627770A (zh) | 2013-11-18 | 2019-12-31 | 福马疗法公司 | 作为bet溴域抑制剂的四氢喹啉组成物 |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| CA3025988A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
| US20250129055A1 (en) * | 2020-11-19 | 2025-04-24 | Beijing Increase Innovative Drug Co., Ltd. | Glucoside derivative, and preparation method therefor and application thereof |
| CN117321060A (zh) * | 2021-04-18 | 2023-12-29 | 洛桑联邦理工学院 | 用于化学反应的绿色溶剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| KR100591585B1 (ko) | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| NZ521369A (en) | 2000-03-17 | 2004-07-30 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| SK287811B6 (sk) | 2000-09-29 | 2011-10-04 | Kissei Pharmaceutical Co., Ltd | Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| ES2363941T3 (es) * | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| CA2525764C (en) | 2003-05-20 | 2012-07-17 | Novartis Ag | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
| WO2005011592A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indazole-o-glucosides |
| ES2531660T3 (es) * | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| EP1660509B1 (de) | 2003-08-26 | 2009-02-04 | Boehringer Ingelheim International GmbH | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| PL381247A1 (pl) | 2004-03-04 | 2007-05-14 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze |
| BRPI0508259A (pt) | 2004-03-04 | 2007-07-31 | Kissei Pharmaceutical | derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2006010557A1 (de) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7750145B2 (en) | 2004-11-18 | 2010-07-06 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| US8541380B2 (en) * | 2009-06-19 | 2013-09-24 | Green Cross Corporation | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2012
- 2012-04-12 JP JP2014504431A patent/JP2014510782A/ja active Pending
- 2012-04-12 CN CN201280028538.2A patent/CN103619862A/zh active Pending
- 2012-04-12 WO PCT/IB2012/051798 patent/WO2012140596A1/en not_active Ceased
- 2012-04-12 BR BR112013026361A patent/BR112013026361A2/pt not_active IP Right Cessation
- 2012-04-12 EA EA201391524A patent/EA201391524A1/ru unknown
- 2012-04-12 EP EP12719082.5A patent/EP2697240B1/en active Active
- 2012-04-12 MX MX2013011926A patent/MX2013011926A/es not_active Application Discontinuation
- 2012-04-12 US US13/634,597 patent/US8722633B2/en active Active
- 2012-04-12 KR KR1020137029814A patent/KR20140019834A/ko not_active Withdrawn
- 2012-04-12 CA CA2832951A patent/CA2832951A1/en not_active Abandoned
- 2012-04-12 AU AU2012241426A patent/AU2012241426A1/en not_active Abandoned